A detailed history of Fieldpoint Private Securities, LLC transactions in Repligen Corp stock. As of the latest transaction made, Fieldpoint Private Securities, LLC holds 105 shares of RGEN stock, worth $13,096. This represents 0.0% of its overall portfolio holdings.

Number of Shares
105
Previous 279 62.37%
Holding current value
$13,096
Previous $52,000 67.31%
% of portfolio
0.0%
Previous 0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 05, 2022

SELL
$140.68 - $188.02 $24,478 - $32,715
-174 Reduced 62.37%
105 $17,000
Q1 2022

Apr 07, 2022

BUY
$161.19 - $257.96 $967 - $1,547
6 Added 2.2%
279 $52,000
Q4 2021

Jan 24, 2022

BUY
$247.59 - $304.47 $3,218 - $3,958
13 Added 5.0%
273 $72,000
Q3 2021

Nov 12, 2021

BUY
$194.77 - $324.21 $13,633 - $22,694
70 Added 36.84%
260 $75,000
Q1 2021

Apr 23, 2021

BUY
$180.37 - $226.26 $901 - $1,131
5 Added 2.7%
190 $37,000
Q4 2020

Jan 28, 2021

BUY
$148.08 - $206.57 $27,394 - $38,215
185 New
185 $35,000

Others Institutions Holding RGEN

About REPLIGEN CORP


  • Ticker RGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 55,491,200
  • Market Cap $6.92B
  • Description
  • Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....
More about RGEN
Track This Portfolio

Track Fieldpoint Private Securities, LLC Portfolio

Follow Fieldpoint Private Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fieldpoint Private Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fieldpoint Private Securities, LLC with notifications on news.